BACKGROUND:
1p36 deletion syndrome can predispose to pediatric-onset cardiomyopathy. Deletion breakpoints are variable and may delete the transcription factor
PRDM16
. Early studies suggest that deletion of
PRDM16
may underlie cardiomyopathy in patients with 1p36 deletion; however, the prognostic impact of
PRDM16
loss is unknown.
METHODS:
This retrospective cohort included subjects with 1p36 deletion syndrome from 4 hospitals. Prevalence of cardiomyopathy and freedom from death, cardiac transplantation, or ventricular assist device were analyzed. A systematic review cohort was derived for further analysis. A cardiac-specific
Prdm16
knockout mouse (
Prdm16
conditional knockout) was generated. Echocardiography was performed at 4 and 6 to 7 months. Histology staining and qPCR were performed at 7 months to assess fibrosis.
RESULTS:
The retrospective cohort included 71 patients. Among individuals with
PRDM16
deleted, 34.5% developed cardiomyopathy versus 7.7% of individuals with
PRDM16
not deleted (
P
=0.1). In the combined retrospective and systematic review cohort (n=134),
PRDM16
deletion-associated cardiomyopathy risk was recapitulated and significant (29.1% versus 10.8%,
P
=0.03).
PRDM16
deletion was associated with increased risk of death, cardiac transplant, or ventricular assist device (
P
=0.04). Among those
PRDM16
deleted, 34.5% of females developed cardiomyopathy versus 16.7% of their male counterparts (
P
=0.2). We find sex-specific differences in the incidence and the severity of contractile dysfunction and fibrosis in female
Prdm16
conditional knockout mice. Further, female
Prdm16
conditional knockout mice demonstrate significantly elevated risk of mortality (
P
=0.0003).
CONCLUSIONS:
PRDM16
deletion is associated with a significantly increased risk of cardiomyopathy and cardiac mortality.
Prdm16
conditional knockout mice develop cardiomyopathy in a sex-biased way. Patients with
PRDM16
deletion should be assessed for cardiac disease.